Dr. Reddy’s Laboratories agrees to sell its U.S. and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg to Upsher-Smith Laboratories for $70M upfront.
In addition, agreement calls for $40.5M in near-term milestones and additional financial considerations including existing contractual obligation and inventory.
Dr. Reddy’s will also get sales-based royalties on a quarterly basis.
Date: June 17, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Seeking Alpha